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Abstract: Fluorescence-based detection assays play an essential role in the life sciences and medicine.
To offer better detection sensitivity and lower limits of detection (LOD), there is a growing need
for novel platforms with an improved readout capacity. In this context, substrates containing
semiconductor nanowires may offer significant advantages, due to their proven light-emission
enhancing, waveguiding properties, and increased surface area. To demonstrate and evaluate the
potential of such nanowires in the context of diagnostic assays, we have in this work adopted a well-
established single-chain fragment antibody-based assay, based on a protocol previously designed
for biomarker detection using planar microarrays, to freestanding, SiO2-coated gallium phosphide
nanowires. The assay was used for the detection of protein biomarkers in highly complex human
serum at high dilution. The signal quality was quantified and compared with results obtained
on conventional flat silicon and plastic substrates used in the established microarray applications.
Our results show that using the nanowire-sensor platform in combination with conventional readout
methods, improves the signal intensity, contrast, and signal-to-noise by more than one order of
magnitude compared to flat surfaces. The results confirm the potential of lightguiding nanowires for
signal enhancement and their capacity to improve the LOD of standard diagnostic assays.
Keywords: antibody microarray; nanowire sensors; biomarker discovery
1. Introduction
Due to their versatility and practical applicability, fluorescence-based readout assays
play an essential role in life sciences and medicine [1], with applications spanning from
live-cell imaging [2] and protein interaction kinetics and folding [3] to in vitro and in vivo
medical diagnostics [4]. Despite their ubiquity, constant efforts are made to improve both
their sensitivity and specificity. For instance, in the context of diagnostics [5], lowering the
limit of detection (LOD) is central to achieving reliable identification of low-abundance
biomarkers, which is a prerequisite for early diagnosis [6]. Efforts towards this aim include
the development of high-sensitivity photodetectors [7], high-quantum yield and photo-
stable fluorescent probes (both organic [8,9] and inorganic [10]), and more recently, efficient
means to interface high-affinity biomolecular interaction partners with nanostructure-based
fluorescence enhancement platforms.
The nanomaterials so far predominantly explored for the latter purpose are primar-
ily metallic nanoparticles, providing plasmonic-induced fluorescent enhancement [11,12].
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In the context of optical biosensor applications, semiconductor nanowires have been mostly
explored on the basis of their higher surface area compared with planar substrates, but they
have recently gained increased attention also due to their highly advantageous optical
properties [13–15]. Specifically, nanowires have been shown to collect the fluorescence
emission of a large number of surface-bound fluorophores and re-emit it at their tip, not un-
like an optical fiber [16], thereby greatly enhancing the overall intensity of the emission
and even enabling single-molecule detection without advanced optics [17]. In addition to
the effect of the increased surface area offered by the nanowires, which increases the total
fluorescence signal within the field-of-view, the signal is furthermore enhanced due to a
combination of advantageous physical effects: (i) the relatively high refractive index of
semiconductor nanowires enables them to support waveguide modes at small diameters,
collecting and guiding the emission from fluorophores placed in immediate proximity
to the nanowire surface [16,18]; (ii) it has been suggested that the coupling of excitation
light in waveguide modes can increase the intensity of the local electromagnetic field
close to the nanowire’s surface, enhancing the excitation of fluorophores placed in their
close proximity [19,20]; and (iii), the emission of light from the nanowire tip can be highly
directional, thereby increasing the light collection efficiency of the readout system.
Several studies, employing different semiconductor materials (e.g., ZnO [21], Si [22],
GaP [14], InAs [23], GaAs [19]), have addressed the potential of nanowires to enhance
fluorescent signals. Among them, some investigated the physical interactions between
nanowires and fluorescent dyes suitable for biomolecular labeling [15,16,18,20], for example
showing how guiding efficiency is strongly dependent on nanowire material, diameter, and
light wavelength, with different diameters maximizing efficiency for a certain wavelength
range, allowing optimization for selected fluorophores [16]. Others explored their use
for investigating biological systems, such as molecular motors [14], supported lipid bilay-
ers [17], and live cells [19]. Patterned arrays of spatially ordered ZnO nanowires have been
used for protein microarray applications, demonstrating detection limits in the fM regime,
even beating state-of-the-art ELISA platforms when applied both on human samples and
serum spiked with carefully controlled biomarker concentrations [20,24]. Although the
exact magnitude of the fluorescence enhancement provided by nanowires has been subject
to intense evaluations [20], quantitative measurements of the enhancement provided by
nanowires have been so far scarce, in terms of immunoassays tested, and focused on ZnO
nanowires [20,24]. Compared to ZnO, the GaP NWs used in this study have a considerably
higher refractive index, allowing them to support waveguide modes at smaller diameters
and guide light more efficiently than their ZnO counterparts. Moreover, in contrast to
solution-processed ZnO nanowires, GaP wires can be synthesized using epitaxy, which
allows for enhanced control over the nanowire size and shape, resulting in a homogeneous
nanowire population with geometries precisely matched for optimal signal enhancement.
In many fluorescence-based detection assays, including antibody-based microarrays,
a high signal intensity does not necessarily imply reliable data, because what matters is
primarily the relative intensity of the signal compared to background. For this reason,
contrast and signal-to-noise ratio are preferred quantities to use when evaluating how well
a signal of interest can be resolved [25]. In this work, we therefore use these measures to
assess the capacity of SiO2-coated GaP nanowires for the detection of biomarkers using a
well-established immunoassay originally designed for flat surfaces [26] and proven capable
of identifying unique biomarker signatures for cancer diagnostics [27,28]. Specifically, the
nanowire platform is compared with flat, SiO2-coated silicon substrates, and to MaxiSorp
plastic slides, the latter being the standard platform for this particular single chain fragment
variable (scFv) antibody-based microarray assay [26,29]. ScFv can easily be produced in
bacterial culture and we have earlier shown their high suitability for both the generation of
libraries and the use in high-throughput multiplexed applications [26,30], allowing to assess
how nanowires could impact a state-of-the-art system. Moreover, the fact that ScFv are well
adsorbed on negatively charged surfaces (such as MaxiSorp or SiO2) makes the testing of
silica-coated nanowire samples possible without any additional surface functionalization.
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The performance of the three types of surfaces named above is evaluated using five different
scFv antibodies directed against different biomarkers, the expression of which being
correlated with several different diseases, for example lung and pancreas cancer (CEACAM-
1) [31,32], asthma (IL-5) [33], and heart disease (MCP-1) [34]. For these biomarkers, we
analyze the total fluorescent signal intensity, the Weber contrast, and the signal to noise
ratio (SNR) and find that all three parameters are more than an order of magnitude larger
on nanowire substrates compared to flat substrates. Moreover, at low serum concentrations,
where no signal could be detected on flat substrates, a quantifiable signal could still be
obtained on nanowires. Taken together, our results show that lightguiding nanowire
substrates have a significant potential as a platform for ultrasensitive, fluorescence-based
biomarker detection when low detection limits are needed.
2. Materials and Methods
2.1. GaP Nanowires Synthesis
GaP nanowires were grown on (111)B GaP substrates using metalorganic vapor
phase epitaxy (MOVPE) from 50 nm Au seed nanoparticles randomly deposited on the
substrate at a density of approximately 0.35 µm−2 [35]. At this density, the average distance
between nanowires is ~3 µm, sufficiently larger than one wavelength (~650 nm) to avoid
waveguide mode superposition between nanowires. Two batches of nanowire substrates
were used in this study, grown (i) axially to a length of 4.1 ± 0.1 µm and then radially to a
diameter of 160 ± 7 nm and (ii) to a length of 3.7 ± 0.1 µm and a diameter of 160 ± 7 nm,
respectively (Figure 1). The specific diameter allows for optimal in-coupling of light
emitted by fluorophores in the red spectral range (such as for the dye Alexa647 used in
the current experiments), due to the presence of partially localized waveguide modes.
The small variations in diameter between nanowires in the same batch are not expected to
significantly impact their waveguiding properties, in particular considering the line width
of the fluorophores [16]. Nanowire samples and flat Si substrates were coated with ~10 nm
of silicon oxide (SiO2) using atomic layer deposition (ALD).
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(perpendicular view).
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2.2. Biotinylation of Serum Samples
Biotinylation of serum was performed on ice or at 4 ◦C according to standard pro-
cedure. Briefly, serum samples were centrifuged at 16,000× g and the resulting cleared
serum then diluted in PBS (D-PBS-Sterile w/o Mg, Ca, GE Healthcare Life Sciences, Marl-
borough, MA, USA) to 1:5 before the addition of biotin (EZ-LinkTM NHS-PEG4-Biotin,
Thermo Fisher Scientific, Waltham, MA, USA) to a final concentration of 1.13 mM. The reac-
tion was terminated after 2 h by adding Tris-HCl pH 8.0 (Thermo Fisher Scientific, Waltham,
MA, USA) to a final concentration of 181 mM. For each biotinylation plate, three replicates
of a reference serum sample (ERM-DA470k/IFCC, JRC, Geel, Belgium) were included as
the process control. Biotinylated samples were pooled, aliquoted, and stored at −80 ◦C.
2.3. scFv Production
Human recombinant single-chain Fv antibodies were purified from E. coli, using
His MultiTrap FF 96 well plates (GE Healthcare Life Sciences, Marlborough, MA, USA),
according to the manufacturer’s instructions. Buffer exchange to PBS (GE Healthcare Life
Sciences) was performed using ZebaTM 96-well desalt spin plates (Thermo Fisher Scientific,
Waltham, MA, USA). Sodium azide (GBiosciences, Saint Louis, MO, USA) was added to the
purified scFv in PBS to a final concentration of 0.06%. The purity of the scFvs was evaluated
by SDS-PAGE, using 8–16% Criterion™ TGX Stain-Free™ Protein Gel (BioRad, Hercules,
CA, USA). Concentrations were measured in a SPECTROstar Omega microplate reader at
280 nm and analyzed with the included MARS software (BMG Labtech, Ortenberg, Ger-
many). PC013 and PC070 were produced at the Department of Immunotechnology, Lund
University, Sweden, and RD003, RD004, and RD017 at Immunovia AB, Lund, Sweden.
2.4. Sample Functionalization
The assay used in this study was adapted from an assay developed for scFv mi-
croarrays [29] on black polymer MaxiSorp slides (NUNC A/S) [26]. The same assay was
run on three different substrates: (i) SiO2-coated nanowire substrates, (ii) SiO2-coated,
flat silicon substrates, and (iii) flat MaxiSorp slides, henceforth referred to as nanowire,
silicon, and MaxiSorp substrates, respectively. Prior to scFv spotting, the nanowire and
silicon substrates were ozone-preened for 40 min in order to clean and activate the surface,
glued to a MaxiSorp slide, and placed in a 12-well slide holder. Spotting of antibodies
was done by manually depositing 1.5 µL of scFv solution on each type of substrate. This
resulted in the silicon and MaxiSorp substrates having only part of their surface exposed
to the scFv solution. In contrast, the smaller and more hydrophilic nanowire substrates
were entirely covered by the scFv solution. All substrates were then incubated at room
temperature in a moist environment for about 20 h in stagnant conditions to facilitate scFv
adsorption. After incubation, the substrates were rinsed thoroughly with 0.05% Tween 20
solution in PBS to remove the excess antibodies, then incubated on an orbital shaker for
one hour with a blocking solution (1 w% fat-free milk powder, 1% Tween solution in PBS)
to passivate the surface. The substrates were then rinsed thoroughly with 0.05% Tween
solution in PBS and incubated for two hours in biotinylated serum diluted in blocking
solution. The substrates were rinsed four times with 0.05% Tween solution in PBS and
incubated on an orbital shaker with 10 µM Streptavidin-Alexa 647 in blocking solution for
one hour, then rinsed with MilliQ water and dried with nitrogen (see Figure 2a–c for a
schematics of the assay). All incubation steps were performed at room temperature while
shielding the samples from light.
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Figure 2. (a) Schematic representation of the single chain fragment variable (scFv) assay used in this study. ScFv antibodies
(pink) are physisorbed on a surface. A blocking agent (green) is subsequently used to minimize unspecific binding of
biotinylated serum proteins (blue), which are targeted by fluorescently labelled streptavidin (dark red). (b,c) Schematic
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between specific an unspecific binding to the antibodies.
2.5. Sample Imaging
All sa ples were imaged within a few hours from preparation in epifluorescence using
a custom-built microscope, a 40×, 0.85 NA air objective (Nikon, Tokyo, Japan), a Prime95B
scientific CMOS camera (Photometrics, Tucson, AZ, USA), and a high-power LED source
(Thorlabs, Newton, NJ, USA) for illumination (emission peak at 625 nm). The lamp power
was kept at 15% (~15 mW) to limit bleaching. The camera exposure time was set to 500 ms
(See Figure 2d–f for raw images of the signal collected from each substrate). A total of five
different scFv were used in this study and duplicates were made for each scFv and for each
substrate. Th scFv target and spotting concentrations are reported in Table 1. Henceforth,
ach scFv type will be referred to by its tag number.
In the standard protocol used for these scFv, biotinylated serum is further diluted to
2% in blocking solution. However, to better test the enhancement provided by nanowires,
the standard solution was further diluted by factors of 1:5 (0.4%), 1:10 (0.2%), and 1:20
(0.1%), henceforth referred to as 0.4%, 0.2%, and 0.1%, respectively. Two control samples
were prepared for each substrate type to estimate nonspecific binding: one by exposing
scFv-spotted substrates to a solution containing no serum (0%), and one by exposing
non-spotted surfaces to the highest serum concentration used in this study (0.4%).
For silicon and MaxiSorp substrates, where the edge of the scFv spot could be iden-
tified (Figure 2d,e), the signal intensity Is and background intensity IB were extracted
as the mean pixel value corresponding to regions inside and outside the scFv spot,
respectively (Figure 3a).
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Table 1. Target and spotting concentration of single chain fragment variable (scFv), with typical biomarker concentrations
in patients.
ScFv Target Biomarker Spotting scFv Conc. (mg/mL) Typical biomarker Concentration (pg/mL)
PC013 Interleukin-5 (IL-5) 0.111 ~10 (asthmatic) [33]~1 (healthy) [36]
PC070 Monocyte chemoattractant protein(MCP-1) 0.139
~5 × 102 (diabetic) [37]




cell adhesion molecule 1
(CEACAM-1)
0.300
~ 5 × 105 (lung cancer) [31]
~1.5 × 105 (melanoma) [39]
~6 × 105 (healthy) [40]
RD004
Carcinoembryonic antigen-related
cell adhesion molecule 1
(CEACAM-1)
0.300
RD017 Cytotoxic T-lymphocyte-associatedprotein 4 (CTLA-4) 0.230
Large dynamic range reported:
~102 (cancer patients) [41]
~2 × 103 (primary proliferative
glomerulonephritides) [42]
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Figure 3. Image analysis for signal extraction on (a) MaxiSorp black polymer plastic spotted with antibodies and exposed to
0.4% serum concentration, (b) scFv-spotted nanowires exposed to 0.4% serum concentration, and (c) non-spotted nanowires
exposed only to 0.4% serum concentration (control sample). Panel (a) is displayed in a different pixel window than panels
(b,c) to better show the contrast between spotted and non-spotted areas in (a). On flat substrates, the signal and background
intensity are extracted as the mean pixel value in the areas inside (blue) and outside (red) the scFv spot, respectively.
On nanowire samples, Is is the mean pixel intensity on anowir positions, (highlighted in blue in (b)). Similarly, IB is the
mean pixel intensity on nanowire positions on the control substrate (red in (c)).
However, due to the non-homogeneous nature of the nanowire substrates, the analysis
on nanowires had to be performed in a slightly different manner. In the analysis, wires were
defined as regions containing more than five bright pixels after the image had been pro-
cessed with a Laplacian and threshold filters. The signal intensity, Is, for each wire was then
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calculated as the mean pixel value of the region defining the wire (Figure 3b). Because SiO2-
coated nanowire substrates are very hydrophilic after ozone preening, and since the sam-
ples used in our study are relatively small (<5 mm2), the spotting of scFv fragments on
a nanowire substrate inevitably resulted in the scFv fragment drop covering the entire
surface of the sample, making it impossible to extract IB from a non-spotted area on the
same substrate. Instead, the background intensity IB on nanowire substrates was designed
as the mean pixel value at the positions of nanowires on substrates that were not exposed
to scFv fragments but exposed to serum only (Figure 3c).
3. Results
The assay used in this study was originally developed for antibody microarrays [29]
on black polymer MaxiSorp slides (NUNC A/S) [26], and it was run on three different
substrates: (i) SiO2-coated nanowire substrates, (ii) SiO2-coated, flat silicon substrates
and (ii) flat MaxiSorp slides (see Figure 2). A total of five different scFv (Table 1) were
spotted manually on the different substrates followed by surface passivation, incubation
in biotinylated serum, and incubation in Streptavidin-Alexa Fluor 647 (see Materials and
Methods for detailed experimental protocol) before imaging by fluorescence microscopy.
Signal intensity, Weber contrast, and signal-to-noise ratio were extracted from the
acquired microscopy images of the three different substrate types after rinsing in water and










where σB is the pixel-value standard deviation of the background. The Weber contrast CW,
which is also commonly referred to as the signal-to-background ratio in the literature, is a
measure of the relative intensity of the signal compared to the background. The signal-
to-noise ratio (sometimes referred as the signal-to-standard-deviation ratio, or SSR) is
instead a measurement of how well the signal stands out over the noise fluctuations. IS,
CW, and SNR for the three substrates and the five scFv types after exposure to 0.4% serum
concentration are plotted in Figure 4 (left).
For each scFv and serum concentration, the flat silicon and MaxiSorp substrates
exhibit almost undetectable fluorescent signal intensities. In contrast, IS on nanowires is
higher by a factor 10–20 compared to flat surfaces, in agreement with previous findings
obtained on ZnO nanowires [20]. Similarly, the Weber contrast and SNR are higher on
nanowires (CW ≈ 2–3; SNR > 10) compared to flat surfaces (CW ≈ 0.1–0.2; SNR ≈ 1–2).
For comparison, in the case of DNA microarrays, a commonly applied positive detection
threshold is set to CW ≈ 0.5 [43], and SNR ≈ 3 [44].
Reduction of the biomarker concentrations by decreasing the serum concentration
results in a lowered signal intensity, Weber contrast, and SNR for all antibodies. For the
most diluted samples tested (0.1%), it was in fact not possible to effectively measure the
signal intensity on silicon and MaxiSorp substrates for some antibodies, since it was too
close to that of the background to discern the edges of the scFv droplet (see Figure 3e,f).
In contrast, for the same serum concentration, nanowires consistently exhibited higher
signals than the background (Figure 4, right column).
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Figure 4. Left: extracted values of signal intensity Is, eber contrast CW, and signal to noise ration (SNR) for the various
scFvs on the three substrates tested with 0.4% serum concentration. All three parameters are consistently higher on the
nanowire substrates. Right: example of the effect of serum concentration for the PC070 scFv. Decreasing the serum
concentration results in a decrease in the signal, with 0.1% concentration approaching the limit for reliable signal on
nanowires. Data for all tested scFvs are shown in the Figure S1. Comparison graph in logarithmic scale are shown in
the Figure S2.
4. Discussion
We used lightguiding, free standing GaP nanowires in a scFv antibody-based im-
munoassay and tested five different antibodies for the detection of biomarkers in human
serum. We compared the signal intensity, signal contrast, and SNR obtained on nanowires
compared to those on commonly used flat substrates. For all antibodies, the increase in
signal intensity, contrast, and SNR is more than one order of magnitude larger on the
nanowires compared to flat silicon and MaxiSorp substrates, proving that GaP nanowires
can be used effectively for signal enhancement in immunoassays. Control experiments
(i.e., spotted samples not exposed to serum and not-spotted samples exposed to serum)
showed a consistently lower fluorescent signal compared to the respective experiments,
verifying that unspecific binding to the surfaces played an insignificant role. Moreover,
signal intensity of control experiments showed limited variations between experiments.
The observed variation in SNR and CW, between different antibodies, can be attributed to
differences in the adsorption of different antibodies and in the respective biomarker con-
centration. In addition, the process of manually spotting the samples also could contribute
to signal variations, since manual spotting is inherently more prone to deviations than, for
example, inkjet printing, which is commonly used to produce protein microarrays. Sample
drying could have an effect as well, as the nanostructured surfaces cannot be blow-dried at
high pressure.
It is worth noting that the assay used in this study is routinely used for antibody
microarrays on MaxiSorp slides and was implemented on nanowires with minimal de-
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viation from the routine protocol. The majority of the nanowires go through the process
of repeated rinsing and drying steps with little or no damage. This shows that nanowire
substrates are a sturdy platform, allowing for an easy implementation of pre-existing
assays. In addition, the use of ALD enables the coating of nanowires with different mate-
rials, depending on surface chemistry needs. Altogether, our results indicate that using
semiconductor nanowire substrates instead of standard flat substrates with fluorescence
detection assays will improve the limit of detection, making them valuable for the detection
of low abundance molecules in biological fluids. The results presented here are general
to other types of nanowires made of high refractive index materials, as the lightguiding
properties of nanowires depend directly on the refractive index difference between the
nanowire and surrounding medium.
5. Conclusions
It is clear from the results presented in this study that the high surface-to-footprint ratio
of the nanowires, combined with their lightguiding properties, could be used to greatly
increase the detection limit of immunoassays or, alternatively, to decrease the amount of
biological material required. Moreover, the increased signal quality on nanowires at very
low serum concentrations opens up possibilities for developing a platform able to reliably
detect very low abundance biomarkers in complex proteomes, important in, for example,
the context of early-stage cancer detection [27,45] or miniaturization of diagnostic tools [46].
Although the aim of this work was not to quantify the limit of detection in terms of target
concentration, which requires biomarker-free serum spiked with pure biomarker, it is
worthwhile noting that while the serum dilution for the standard protocol developed
for antibody microarray on the MaxiSorp Plastic is 2%, a fluorescent signal appreciably
larger than the background could be detected on nanowires exposed to serum 20 times
less concentrated (0.1%). For example, the typical concentration of MCP-1 (targeted by
PC070) is on the order of 100 pg/mL, while that of IL-5 (targeted by PC070) is on the
order of 10 pg/mL. A 20-fold increase in sensitivity raises the prospect of a limit of
detection below 1 pg/mL (i.e., ~10–100 fM), which is comparable with state-of-the-art
immunoassays [47]. Further work is necessary to precisely estimate the gain in LOD using
a nanowire substrate, but these results prove how nanowires can substantially improve
detection in a realistic assay (i.e., using human serum with native biomarker). In light of
the fact that high-quality nanowire platforms are now becoming available at low cost, this
makes this approach highly attractive in the intense search for simple biosensor formats
offering reliable detection of low-abundance biomarkers.
Supplementary Materials: Supporting Information contains results for all the tested serum concen-
trations for all the antibodies tested and Figure 4 displayed in logarithmic scale. The following are
available online at https://www.mdpi.com/2079-4991/11/1/227/s1, Figure S1: Data for all tested
scFvs, Figure S2: Figure 4 plotted in logarithmic scale.
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